Cargando…

Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors

OBJECTIVE: To investigate the effects of CIK (cytokine-induced killer) cell therapy combined with camrelizumab on the quality of life in patients with nasopharyngeal carcinoma and prognostic factors. METHODS: In this retrospective study, the materials of 80 patients with nasopharyngeal carcinoma tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Tao, Luo, Xiu, Cao, Wenping, Man, Rongjun, Feng, Xinrong, Song, Yujie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110146/ https://www.ncbi.nlm.nih.gov/pubmed/35586106 http://dx.doi.org/10.1155/2022/5655009

Ejemplares similares

Retracted: Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors
por: Neuroscience, Computational Intelligence and
Publicado: (2022)

Case Report: Chemotherapy and Radiotherapy Combined With DC-CIK for Pulmonary and Mediastinal Metastases From Nasopharyngeal Carcinoma
por: Gan, Yi-Xiu, et al.
Publicado: (2022)

Identification of Key Genes in Nasopharyngeal Carcinoma Based on Bioinformatics Analysis
por: Song, Yujie, et al.
Publicado: (2022)

Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
por: Lin, Jieheng, et al.
Publicado: (2021)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
por: Yang, Yunpeng, et al.
Publicado: (2021)

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
por: Yuan, Li, et al.
Publicado: (2023)

An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers
por: Yu, Yi, et al.
Publicado: (2021)

Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer
por: Liu, Guiyuan, et al.
Publicado: (2022)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
por: Xiao, Yongqiang, et al.
Publicado: (2023)

Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
por: Zhang, Yajing, et al.
Publicado: (2013)

Combination treatment of pembrolizumab with DC-CIK cell therapy for advanced hepatocellular carcinoma: A case report
por: Huang, Shao M., et al.
Publicado: (2023)

Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol
por: Huang, Jun Tao, et al.
Publicado: (2023)

Innovative Clinical Perspectives for CIK Cells in Cancer Patients
por: Introna, Martino, et al.
Publicado: (2018)

CD300LG improves the cytotoxic activity of CIK
por: Wang, Qiuyue, et al.
Publicado: (2017)

Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer
por: Pan, Mei-Ren, et al.
Publicado: (2019)

Killing effects of Huaier Granule combined with DC-CIK on nude mice transplanted with colon carcinoma cell line
por: Sun, Wen-Wen, et al.
Publicado: (2017)

Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial
por: Li, Jian-Xu, et al.
Publicado: (2022)

Efficacy study of CyberKnife stereotactic radiosurgery combined with CIK cell immunotherapy for advanced refractory lung cancer
por: WANG, YUAN-YUAN, et al.
Publicado: (2013)

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study
por: Ding, Xi, et al.
Publicado: (2023)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
por: Zhang, Luping, et al.
Publicado: (2016)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
por: Ju, Shuguang, et al.
Publicado: (2022)

Adjuvant Chemotherapy With Sequential Cytokine-Induced Killer (CIK) Cells in Stage IB Non-Small Cell Lung Cancer
por: Li, Da-Peng, et al.
Publicado: (2015)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety
por: Ma, Yue, et al.
Publicado: (2012)

Effect of CIK on multidrug-resistance reversal and increasing the sensitivity of ADR in K562/ADR cells
por: WANG, LEI, et al.
Publicado: (2014)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
por: Wang, Kunlun, et al.
Publicado: (2020)

CIK细胞及其在肺癌治疗中的研究进展
Publicado: (2011)

Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro
por: Zhao, Qun, et al.
Publicado: (2010)

Effects of MICA Expression on the Prognosis of Advanced Non-Small Cell Lung Cancer and the Efficacy of CIK Therapy
por: Chen, Yu, et al.
Publicado: (2013)

Camrelizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: A case report and review of literature
por: Liu, Kai, et al.
Publicado: (2022)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
por: Xiang, Zhanwang, et al.
Publicado: (2023)

Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer
por: Huang, Yahan, et al.
Publicado: (2022)

Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
por: Wei, Xiao-Li, et al.
Publicado: (2022)

Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy
por: Qiao, Yujin, et al.
Publicado: (2022)

Cytokine-induced killer (CIK) cells: from basic research to clinical translation
por: Guo, Yelei, et al.
Publicado: (2015)

Comparative Proteomic Analysis of Lysine Acetylation in Fish CIK Cells Infected with Aquareovirus
por: Guo, Hong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lgh9fknbtbjmgelcpr64gdtkd6